Last reviewed · How we verify

NCT05391646: PER

Pulmonary Embolism Registry

Not yet recruiting Last updated 19 October 2023
What this trial tests

trial in Pulmonary Embolism in 500 participants. Not yet recruiting.

Timeline
31 October 2023
Primary endpoint
16 December 2023
16 June 2026

Quick facts

Lead sponsorUniversidade do Porto
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment500
Start date31 October 2023
Primary completion16 December 2023
Estimated completion16 June 2026

Conditions studied

Sponsor

Universidade do Porto — full company profile →

Who can join

18 and older, any sex, with Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute Pulmonary Embolism (PE) is the most serious clinical presentation of venous thromboembolism (VTE), a leading cause of cardiovascular mortality, exceeded only by stroke and myocardial infarction. Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe chronic form of CTED and it occurs in 2-4% of patients after acute PE. In Portugal little is known about PE epidemiology and its outcomes, including complications like CTED. The main goal of this study is, therefore, to understand PE epidemiology and complications in the northern region of Portugal. This information can enable the organization of a structured health care network that can potentially benefit all PE patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Embolism

Currently open trials in the same condition.

Other Universidade do Porto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05391646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing